Rigel Pharmaceuticals. (RIGL) NASDAQ

$2.62 -0.08 (-2.96%)

Market Cap: $461.72M

As of 11/30/21 11:01 AM EST. Market open.

(RIGL)

Rigel Pharmaceuticals. (RIGL) NASDAQ

$2.62 -0.08 (-2.96%)

Market Cap: $461.72M

As of 11/30/21 11:01 AM EST. Market open.

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® ... read more

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Raul Rodriguez
Full Time Employees
169
CEO Compensation (Base)
$636,540
CEO Compensation (Total)
$3.98M
URL
Address
1180 Veterans Blvd, California, South San Francisco, 94080-1985.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Raul Rodriguez
Full Time Employees
169
CEO Compensation (Base)
$636,540
CEO Compensation (Total)
$3.98M
URL
Address
1180 Veterans Blvd, California, South San Francisco, 94080-1985.
KEY STATS
Open
$2.62
Previous Close
$2.70
Days Range
$2.69 - $2.86
52 week range
$2.69 - $5.50
Volume
310,102
Avg. Volume (30 days)
1,857,611
Market Cap
$461.72M
Dividend Yield
0.00%
P/E
-31.82
Shares Outstanding
171,006,061
Open
$2.62
Previous Close
$2.70
Days Range
$2.69 - $2.86
52 week range
$2.69 - $5.50
Volume
310,102
Avg. Volume (30 days)
1,857,611
Market Cap
$461.72M
Dividend Yield
0.00%
P/E
-31.82
Shares Outstanding
171,006,061

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR RIGEL PHARMACEUTICALS
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Schorno Dean L EVP &Chief Financial Officer May 22, 2019 Buy $2.13 50,000 106,544 50,000 May 23, 2019, 08:21 PM
Cabatuan Nelson Principal Accounting Officer Oct 12, 2018 Sale $3.12 10,000 31,200 58 Oct 16, 2018, 06:46 PM
Duliege Anne-Marie EVP & Chief Medical Officer Sep 17, 2018 Option Exercise $2.43 153,000 372,495 115,500 Sep 19, 2018, 06:26 PM
Duliege Anne-Marie EVP & Chief Medical Officer Sep 17, 2018 Sale $3.50 153,000 535,500 0 Sep 19, 2018, 06:26 PM
Mayer Eldon C. III EVP & Chief Commercial Officer Sep 11, 2018 Buy $3.23 50,000 161,340 215,000 Sep 12, 2018, 12:00 AM
Mayer Eldon C. III EVP & Chief Commercial Officer Sep 10, 2018 Buy $3.28 50,000 164,210 165,000 Sep 12, 2018, 12:00 AM
Duliege Anne-Marie EVP & Chief Medical Officer Sep 04, 2018 Option Exercise $2.54 16,500 41,910 16,500 Sep 06, 2018, 07:02 PM
Duliege Anne-Marie EVP & Chief Medical Officer Sep 04, 2018 Sale $3.51 16,500 57,861 0 Sep 06, 2018, 07:02 PM
Mayer Eldon C. III EVP & Chief Commercial Officer Aug 23, 2018 Buy $2.82 100,000 282,320 115,000 Aug 27, 2018, 07:49 PM
RODRIGUEZ RAUL R CEO, President Aug 17, 2018 Buy $2.63 114,000 300,002 173,519 Aug 21, 2018, 07:12 PM
Duliege Anne-Marie EVP & Chief Medical Officer Jul 02, 2018 Sale $2.79 5,000 13,932 0 Jul 05, 2018, 06:59 PM
Duliege Anne-Marie EVP & Chief Medical Officer Apr 20, 2018 Sale $4.11 5,000 20,550 0 Apr 24, 2018, 09:06 PM
Maynard Ryan D EVP & CFO Nov 03, 2017 Option Exercise $2.14 100,000 214,000 100,000 Nov 07, 2017, 09:07 PM
Maynard Ryan D EVP & CFO Nov 03, 2017 Sale $3.90 100,000 390,000 0 Nov 07, 2017, 09:07 PM
Duliege Anne-Marie Chief Medical Officer Jul 05, 2017 Sale $2.69 5,000 13,427 0 Jul 07, 2017, 05:39 PM
Duliege Anne-Marie Chief Medical Officer Jan 03, 2017 Sale $2.41 5,000 12,027 0 Jan 13, 2017, 06:02 PM
PAYAN DONALD G EVP, Pres. Discovery&Research Aug 30, 2016 Sale $4.00 5,303 21,214 53,031 Sep 01, 2016, 06:18 PM
PAYAN DONALD G EVP, Pres. Discovery&Research Jun 10, 2015 Option Exercise $2.14 41,666 89,165 100,000 Jun 12, 2015, 07:22 PM
PAYAN DONALD G EVP, Pres. Discovery&Research Jun 10, 2015 Sale $3.68 41,666 153,214 58,334 Jun 12, 2015, 07:22 PM
PAYAN DONALD G EVP, Pres. Discovery&Research Apr 01, 2015 Sale $3.75 10,000 37,518 58,334 Apr 03, 2015, 08:35 PM
VANCE DOLLY EVP Corp. Affairs, G.C., Sect. Dec 18, 2014 Sale $2.22 1,000 2,220 575 Dec 22, 2014, 06:26 PM
VANCE DOLLY EVP Corp. Affairs, G.C., Sect. Dec 18, 2014 Sale $2.22 1,000 2,220 575 Dec 19, 2014, 06:56 PM
PAYAN DONALD G EVP, Pres. Discovery&Research Sep 03, 2014 Sale $2.56 20,000 51,200 68,334 Sep 05, 2014, 06:07 PM
PAYAN DONALD G EVP, Pres. Discovery&Research Feb 24, 2014 Sale $3.71 20,000 74,238 88,334 Feb 26, 2014, 07:21 PM
BVF PARTNERS L P/IL 10% Owner Nov 19, 2013 Sale $2.64 484,622 1,280,274 1,123,848 Nov 20, 2013, 02:13 PM
BVF PARTNERS L P/IL 10% Owner Jun 07, 2013 Buy $3.47 32,700 113,394 1,455,414 Jun 11, 2013, 05:55 PM
Maynard Ryan D EVP & CFO Sep 12, 2012 Option Exercise $6.49 23,302 151,230 23,302 Sep 14, 2012, 07:57 PM
Maynard Ryan D EVP & CFO Sep 12, 2012 Sale $10.67 23,302 248,560 0 Sep 14, 2012, 07:57 PM
VANCE DOLLY EVP Corp. Affairs, G.C., Sect. Sep 13, 2012 Sale $10.43 4,151 43,284 1,103 Sep 14, 2012, 06:45 PM
Maynard Ryan D EVP & CFO Sep 07, 2012 Option Exercise $6.49 23,302 151,230 23,302 Sep 14, 2012, 06:19 PM
Maynard Ryan D EVP & CFO Sep 07, 2012 Sale $10.67 23,302 248,560 0 Sep 14, 2012, 06:19 PM
Maynard Ryan D EVP & CFO Sep 07, 2012 Option Exercise $6.49 34,112 221,387 34,112 Sep 11, 2012, 06:07 PM
Maynard Ryan D EVP & CFO Sep 10, 2012 Option Exercise $6.49 17,586 114,133 17,586 Sep 11, 2012, 06:07 PM
Maynard Ryan D EVP & CFO Sep 10, 2012 Sale $10.52 17,586 184,927 0 Sep 11, 2012, 06:07 PM
Maynard Ryan D EVP & CFO Sep 07, 2012 Sale $10.55 34,112 359,960 0 Sep 11, 2012, 06:07 PM
Maynard Ryan D EVP & CFO Aug 07, 2012 Option Exercise $6.49 1,700 11,033 1,700 Aug 09, 2012, 05:39 PM
Maynard Ryan D EVP & CFO Aug 07, 2012 Sale $10.61 1,700 18,041 1,000 Aug 09, 2012, 05:39 PM
PAYAN DONALD G EVP, Pres. Discovery&Research Jun 19, 2012 Sale $8.70 10,000 87,008 118,234 Jun 20, 2012, 05:45 PM
Flynn James E 10% Owner May 26, 2011 Buy $8.00 301,424 2,411,392 3,204,167 Jun 07, 2011, 05:27 PM
Flynn James E 10% Owner May 26, 2011 Buy $8.00 229,252 1,834,016 2,279,997 Jun 07, 2011, 05:27 PM
Flynn James E 10% Owner May 26, 2011 Buy $8.00 72,800 582,400 762,700 Jun 07, 2011, 05:27 PM
Flynn James E 10% Owner May 26, 2011 Buy $8.00 46,524 372,192 470,425 Jun 07, 2011, 05:27 PM
Flynn James E 10% Owner Nov 03, 2010 Sale $7.55 2,605 19,668 2,050,745 Nov 05, 2010, 05:39 PM
Flynn James E 10% Owner Nov 03, 2010 Sale $7.55 900 6,795 689,900 Nov 05, 2010, 05:39 PM
Flynn James E 10% Owner Nov 03, 2010 Sale $7.55 516 3,896 423,901 Nov 05, 2010, 05:39 PM
Flynn James E 10% Owner Nov 03, 2010 Sale $7.55 3,690 27,860 2,902,743 Nov 05, 2010, 05:39 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
Schorno Dean L EVP &Chief Financial Officer 05/22/2019 106,544
Cabatuan Nelson Principal Accounting Officer 10/12/2018 31,200
Duliege Anne-Marie EVP & Chief Medical Officer 09/17/2018 372,495
Duliege Anne-Marie EVP & Chief Medical Officer 09/17/2018 535,500
Mayer Eldon C. III EVP & Chief Commercial Officer 09/11/2018 161,340
Mayer Eldon C. III EVP & Chief Commercial Officer 09/10/2018 164,210
Duliege Anne-Marie EVP & Chief Medical Officer 09/04/2018 41,910
Duliege Anne-Marie EVP & Chief Medical Officer 09/04/2018 57,861
Mayer Eldon C. III EVP & Chief Commercial Officer 08/23/2018 282,320
RODRIGUEZ RAUL R CEO, President 08/17/2018 300,002
Duliege Anne-Marie EVP & Chief Medical Officer 07/02/2018 13,932
Duliege Anne-Marie EVP & Chief Medical Officer 04/20/2018 20,550
Maynard Ryan D EVP & CFO 11/03/2017 214,000
Maynard Ryan D EVP & CFO 11/03/2017 390,000
Duliege Anne-Marie Chief Medical Officer 07/05/2017 13,427
Duliege Anne-Marie Chief Medical Officer 01/03/2017 12,027
PAYAN DONALD G EVP, Pres. Discovery&Research 08/30/2016 21,214
PAYAN DONALD G EVP, Pres. Discovery&Research 06/10/2015 89,165
PAYAN DONALD G EVP, Pres. Discovery&Research 06/10/2015 153,214
PAYAN DONALD G EVP, Pres. Discovery&Research 04/01/2015 37,518
VANCE DOLLY EVP Corp. Affairs, G.C., Sect. 12/18/2014 2,220
VANCE DOLLY EVP Corp. Affairs, G.C., Sect. 12/18/2014 2,220
PAYAN DONALD G EVP, Pres. Discovery&Research 09/03/2014 51,200
PAYAN DONALD G EVP, Pres. Discovery&Research 02/24/2014 74,238
BVF PARTNERS L P/IL 10% Owner 11/19/2013 1,280,274
BVF PARTNERS L P/IL 10% Owner 06/07/2013 113,394
Maynard Ryan D EVP & CFO 09/12/2012 151,230
Maynard Ryan D EVP & CFO 09/12/2012 248,560
VANCE DOLLY EVP Corp. Affairs, G.C., Sect. 09/13/2012 43,284
Maynard Ryan D EVP & CFO 09/07/2012 151,230
Maynard Ryan D EVP & CFO 09/07/2012 248,560
Maynard Ryan D EVP & CFO 09/07/2012 221,387
Maynard Ryan D EVP & CFO 09/10/2012 114,133
Maynard Ryan D EVP & CFO 09/10/2012 184,927
Maynard Ryan D EVP & CFO 09/07/2012 359,960
Maynard Ryan D EVP & CFO 08/07/2012 11,033
Maynard Ryan D EVP & CFO 08/07/2012 18,041
PAYAN DONALD G EVP, Pres. Discovery&Research 06/19/2012 87,008
Flynn James E 10% Owner 05/26/2011 2,411,392
Flynn James E 10% Owner 05/26/2011 1,834,016
Flynn James E 10% Owner 05/26/2011 582,400
Flynn James E 10% Owner 05/26/2011 372,192
Flynn James E 10% Owner 11/03/2010 19,668
Flynn James E 10% Owner 11/03/2010 6,795
Flynn James E 10% Owner 11/03/2010 3,896
Flynn James E 10% Owner 11/03/2010 27,860
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
06/30/2021
03/31/2021
-0.09%
1Q
06/30/2021
12/31/2020
4.24%
2Q
06/30/2021
06/30/2020
4.38%
4Q
06/30/2021
12/31/2019
5.08%
6Q
06/30/2021
09/30/2019
5.13%
7Q
06/30/2021
12/31/2018
9.58%
10Q
06/30/2021
06/30/2018
13.94%
12Q
06/30/2021
03/31/2018
19.58%
13Q
06/30/2021
06/30/2017
48.98%
16Q
Load More

Period of Report: 06/30/2021

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
03/31/2021
-0.09%
1Q
12/31/2020
4.24%
2Q
06/30/2020
4.38%
4Q
12/31/2019
5.08%
6Q
09/30/2019
5.13%
7Q
12/31/2018
9.58%
10Q
06/30/2018
13.94%
12Q
03/31/2018
19.58%
13Q
06/30/2017
48.98%
16Q
Load More